Oramed

Oramed, Medpace to collaborate on phase II trial

Monday, October 15, 2012 11:54 AM

Oramed, a subsidiary of Jerusalem-based Oramed Pharmaceuticals, a developer of oral drug delivery systems, has retained Medpace as CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »


Oramed Pharma, Medpace collaborate on phase II FDA trial of oral insulin

Wednesday, October 3, 2012 10:19 AM

Oramed Ltd., a subsidiary of Oramed Pharmaceuticals, a developer of oral drug delivery systems, has signed an agreement to retain Medpace as a full-service CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »


Oramed granted Australian patent for core technology

Thursday, January 26, 2012 09:10 AM

Marking a major milestone for the company, Oramed Pharmaceuticals, a developer of oral drug delivery systems, has received approval for a key patent by the Australian Patent Office. The patent covers an important part of Oramed's core technology, which allows for the oral delivery of peptides.

More... »

Oramed completes toxicity trial for ORMD-0801

Thursday, March 24, 2011 12:33 PM

Oramed Pharmaceuticals, a developer of oral delivery systems, successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801. The study was completed under conditions prescribed by the FDA’s Good Laboratory Practices regulations and is the last study required before an IND filing.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs